Latest News
Haisco agrees licensing deal with Nuvectis for two drug candidates
24 June 2026 - Chinese pharmaceutical company Haisco Pharmaceutical Group Co Ltd (SHE:002653) announced on Tuesday that it has entered into an exclusive licensing agreement with Nuvectis, a US biotechnology company.Under the agreement, Haisco has gra...
ZETA SURGICAL reports first patient treated with Zeta TMS Navigation System at HOPE Therapeutics
24 June 2026 - Medical technology manufacturer ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq:NRXP), announced on Tuesday that the first patient has been treated with the FDA-cleared Zeta TMS Navigation System at a HOPE T...
Psilera introduces new synthetic platform to aid neuroplastogen discovery
24 June 2026 - Psilera, a biopharmaceutical company focused on next-generation psychedelics and neuroplastogens, announced on Tuesday a new method for synthesising novel libraries of next-generation neuroplastogens in the ACS Omega Journal.By gaining...
EU approves MAVIRET for acute hepatitis C treatment
23 June 2026 - Clinical-stage biotechnology company Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced on Tuesday that its partner AbbVie (NYSE:ABBV) has received European Commission approval for MAVIRET (glecaprevir/pibrentasvir) to treat acute hepa...
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without ...